Cost-effectiveness of a telemonitoring program (telEPOC program) in frequently admitted chronic obstructive pulmonary disease patients

被引:5
|
作者
Esteban, Cristobal [1 ,2 ,3 ]
Anton, Ane [2 ,4 ,5 ]
Moraza, Javier [1 ,3 ]
Iriberri, Milagros [3 ,6 ]
Larrauri, Mateo [3 ,7 ]
Mar, Javier [2 ,8 ,9 ]
Aramburu, Amaia [1 ,3 ]
Quintana, Jose M. [2 ,3 ,4 ]
机构
[1] Hosp Galdakao, Serv Neumol, Galdakao, Spain
[2] Red Invest Serv Sanitarios & Enfermedades Cronica, Barcelona, Spain
[3] BioCrues Bizkaia Hlth Res Inst, Baracaldo, Spain
[4] Hosp Galdakao, Unidad Invest, Galdakao, Spain
[5] Kronikgune Res Inst, Baracaldo, Spain
[6] Hosp Cruces, Serv Neumol, Baracaldo, Spain
[7] Organ Sanitaria Integrada Barrualde, Atenc Primaria, Galdakao, Spain
[8] OSI Alto Deba, Clin Management Unit, Alto Deba, Spain
[9] Biodonostia Hlth Res Inst, Donostia San Sebastian, Spain
关键词
Chronic obstructive pulmonary disease; telemonitoring; cost-effectiveness; telehealth; HEALTH; CARE;
D O I
10.1177/1357633X211037207
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Chronic obstructive pulmonary disease is a typical disease among chronic and respiratory diseases. The costs associated with chronic disease care are rising dramatically, and this makes it necessary to redesign care processes, including new tools which allow the health system to be more sustainable without compromising on the quality of the care, compared to that currently provided. One approach may be to use information and communication technologies. In this context, we explored the cost-effectiveness of applying a telemonitoring system to a cohort of chronic obstructive pulmonary disease patients with frequent readmissions (the telEPOC programme). We conducted an intervention study with a control group. The inclusion criteria used were having chronic obstructive pulmonary disease (forced expiratory volume in the first second/forced vital capacity < 70%) and having been hospitalised for exacerbation at least twice in the last year or three times in the last 2 years. We estimated the costs incurred by patients in each group and calculated the quality-adjusted life years and incremental cost-effectiveness ratio. Overall, 77 patients were included in the control group and 86 in the intervention group. The raw cost-effectiveness analysis showed that the cost of the telEPOC intervention was significantly lower than that of usual care, while there were no significant differences between the groups in effectiveness. The incremental cost-effectiveness ratio for the intervention was euro175,719.71 per quality-adjusted life-year gained. There were no differences between the intervention group (telemonitoring) and the control group (standard care) from the cost-effectiveness point of view. On the other hand, the intervention programme (telEPOC) was less expensive than routine clinical practice.
引用
收藏
页码:156 / 164
页数:9
相关论文
共 50 条
  • [41] A multidisciplinary pulmonary rehabilitation program for patients with moderately severe chronic obstructive pulmonary disease
    Lin, MC
    Liaw, MY
    Huang, CC
    Tsai, YH
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 1997, 96 (11) : 869 - 873
  • [42] Smoking cessation program preferences of individuals with chronic obstructive pulmonary disease: a qualitative study
    Tregobov, Noah
    Starnes, Kassandra
    Kassay, Saron
    Mahjoob, Maryam
    Chae, Yu seon Sarah
    McMillan, Austin
    Poureslami, Iraj
    PRIMARY HEALTH CARE RESEARCH & DEVELOPMENT, 2024, 25
  • [43] Cost-Utility Analysis of Telemonitoring Interventions for Patients with Chronic Obstructive Pulmonary Disease (COPD) in Germany
    Florian Hofer
    Dmitrij Achelrod
    Tom Stargardt
    Applied Health Economics and Health Policy, 2016, 14 : 691 - 701
  • [44] Cost-Effectiveness Analysis of Triple Combination Preparations in the Treatment of Moderate-to-Severe Chronic Obstructive Pulmonary Disease
    Zhou, Yikang
    Long, Enwu
    Xu, Qian
    Wang, Lei
    Jiang, Xuehua
    Hu, Ming
    FRONTIERS IN PUBLIC HEALTH, 2021, 9
  • [45] Influence of government-driven quality assessment program on patients with chronic obstructive pulmonary disease
    Park, Hye Jung
    Kim, Sung-Ryeol
    Kim, Sinae
    Lee, Hye Sun
    Kim, Bo Yeon
    Kim, Hye Kyoung
    Ahn, Sang In
    Shin, Ji Hyeon
    Lee, Jae-Hyun
    Park, Jung-Won
    RESPIRATORY RESEARCH, 2021, 22 (01)
  • [46] Impact of a Telehealth and Care Management Program for Patients with Chronic Obstructive Pulmonary Disease
    Au, David H.
    Macaulay, Dendy S.
    Jarvis, John L.
    Desai, Urvi S.
    Birnbaum, Howard G.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2015, 12 (03) : 323 - 331
  • [47] Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive pulmonary disease in the UK
    Punekar, Yogesh Suresh
    Roberts, Graeme
    Ismaila, Afisi
    O'Leary, Martin
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2015, 13
  • [48] A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease
    Lock, Kevin
    Wilson, Koo
    Murphy, Daniel
    Antonio Riesco, Juan
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (17) : 2613 - 2626
  • [49] Cost-effectiveness Analysis of Population-based Screening for Chronic Obstructive Pulmonary Disease in China
    Fan, Yiwen
    Chen, Qiushi
    Chen, Simiao
    MEDICAL DECISION MAKING, 2024, 44 (02) : NP9 - NP10
  • [50] Evaluation of a home hospitalization program in patients with exacerbations of chronic obstructive pulmonary disease
    Lobato, SD
    Lorenzo, FG
    Mendieta, MAG
    Alises, SM
    Arechabala, IM
    Fernández-Montes, CV
    ARCHIVOS DE BRONCONEUMOLOGIA, 2005, 41 (01): : 5 - 10